Will Tesla's Giant Move Help NASDAQ Break Out?
Investors Cautious With Election Ahead, Treasury Yields Surge Further, Tesla Surprises: This Week In The Market
Stock Of The Day: Amazon Chart Shows Some Things Are Obvious
Weekly Buzz: Is Tesla a sign of earnings to come?
'Google Plans To Announce Its Next Gemini Model Soon/ December Is Shaping Up To Be A Month Of Dueling Announcements From OpenAI And Google' - The Verge
Friday Market Falls With Busy Business Ahead | Wall Street Today
Apple Stock Vs. Alphabet Stock: Which Magnificent 7 Stock Performs Better In The Long Run?
'Amazon's Top Grocery Stores Exec Tony Hoggett Is Leaving in Big Exit From Senior Leadership Team' GeekWire
Apple's "highly confidential" app testing exposure may help in the research of a fifteen-year history blood glucose monitoring device.
Media reports that the app being tested by apple helps prediabetic patients manage food intake, aiming to explore the possible uses of blood sugar data, and what tools it could create for consumers; Apple has not announced plans to release the app, but may integrate the technology into future health products, including the non-invasive blood glucose monitoring device that began development in the era of Steve Jobs.
Call Of Duty: Black Ops 6's 'Arachnophobia Mode' Redesigns Zombie Spiders — And It's Terrifying
Apple Q4 Earnings Preview: Goldman Sachs Analyst Anticipates Big Earnings Beat, Resilient iPhone 16 Demand
Microsoft CEO Nadella Comp Rose 63% in Fiscal 2024: Filing
Catalyst Watch: Eyes on Tech With Apple, Amazon, Alphabet, and Meta Reporting
Tesla To Rally Over 21%? Here Are 10 Top Analyst Forecasts For Friday
What's Going On With Trump Media & Technology Group Stock On Friday?
Citigroup Maintains Buy on Eli Lilly, Raises Price Target to $1250
Ahead of Q3 Earnings, Bank of America Names Beneficiaries of Surge in Hyperscale Spending
Eli Lilly Analyst Ratings
Michael Saylor's Proposal To Microsoft CEO Satya Nadella: 'If You Want To Make The Next Trillion Dollars For Shareholders, Call Me'
Eli Lilly's Newly FDA-Approved Eczema Drug Improves Skin And Itch In Patients Previously Treated With Sanofi/Regeneron's Dupixent